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Severe Left Ventricular Dysfunction Predicts Mortality In Patients With
Symptomatic Functional Mitral Regurgitation Undergoing Percutaneous
Edge-To-Edge Repair
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Background: Percutaneous edge-to-edge repair is currently being used for the
treatment of symptomatic functional mitral regurgitation (FMR). There is little
data on the efﬁcacy of this therapy in patients with severe left ventricular
dysfunction (SLVD). We sought to determine the impact of SLVD on mortality after
MitraClip.
Methods: Single center prospective registry of patients treated with the MitraClip
under the Compassionate Use Program of Health Canada (Special Access). Patients
were divided into 2 groups: SLVD (left ventricular ejection fraction, LVEF 20%)
and LVEF >20%. The primary endpoint was all-cause mortality.
Results: Sixty-three patients with FMR were treated with MitraClip between
Dec 2010 and Mar 2014 (23.8% female, age 72.210.6 years, LVEF 33.612.8%).
Patients with and without SLVD were not signiﬁcantly different in terms of baseline
characteristics or medical treatment. Patients with SLVD had larger LV dimensions.
Final MR result was similar (MR 2+: 78.6% vs. 87.2%, SLVD vs. LVEF >20%;
p¼0.42), as was in-hospital mortality (7.1% vs. 6.1%, p¼0.89). However, at follow-
up (288277 days) patients with SLVD had higher mortality (42.9% vs. 14.3%,
p¼0.02). SLVD was a predictor of death (HR 3.17; 95% CI: 1.04 to 9.68; p¼0.04),
after adjusting for EuroSCORE II (Figure). There were no differences in the rates of
readmission for heart failure (25.0% vs. 8.6%, p¼0.14).Univariate HR 95% CI p
Age 1.03 0.99-1.07 0.1605
LVEF 1.00 0.96-1.04 0.9456
Log. EuroSCORE 1.02 1.00-1.04 0.0168
Impaired renal function 2.18 0.97-4.87 0.0578
Discharge MR 3+/4+ (vs. 1+/2+) 4.18 1.41-12.5 0.0100
pre-MC TAPSE (per 1-mm decrease) 1.15 1.03-1.28 0.0090
post-MC VCA (per 1-mm2 increase) 1.02 1.00-1.04 0.0096Conclusions: In patients with signiﬁcant FMR, treatment with MitraClip is associated
with a reduction in MR. However, this does not translate into a survival beneﬁt in
patients with a LVEF 20%.
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9HerzKlinik Hirslanden, Zurich, SwitzerlandB232 JACC Vol 64/11/Suppl BBackground: Percutaneous mitral valve repair (MVR) may be a valid alternative
for patients with severe mitral regurgitation (MR) and high operative risk. The use
of the MitraClip-system is therefore constantly growing worldwide despite a
lack of evidence deriving from randomized trials. Data from high volume registries
is therefore still of use and we therefore aim to report on the experience
gained after inclusion of 265 patients in the prospective nationwide MitraSwiss
registry.
Methods: Patients with severe MR (>3+) and high operative risk (as discussed within
a Heart-team) or declined for surgical repair were considered and asked for their
consent to participate to the registry. Percutaneous MitraClip implantation was
performed in the cath-lab setting with trans- esophageal monitoring under general
anesthesia.
Results: Since autumn 2011 a total 265 patients were included in the registry by 8
cardiovascular centers. The mean age was 7710 years (64% male; logEuroScore
1315%; meanSD) with a left ventricular ejection fraction of 4517% (meanSD).
The origin of the MR was functional in 55% and degenerative in 39% of the cases.
In 6% of the patients the cause of the MR was mixed. Acute procedural success
(APS), deﬁned as placement of 1 or more clips resulting in a discharge MR severity of
2+, was achieved in 91% of the cases. The complication rate was low and 30 days
survival was as good as 97.32% (95%CI 94.46-98.71%). At 6 months 80% of the
(visited) patients were in NYHA class 1 or 2 and 75.2% of them had a MR grade of
1+ or 2+.
Conclusions: In Switzerland, all patients which undergo percutaneous MVR are
included in a nationwide prospective registry. After 265 included patients, our
data conﬁrm a high perioperative success rate together with a low complication rate.
30 days and 6 months results are promising. Functional and echocardiographic results
will be available at the time of the meeting.TCT-794
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Background: Implantation of the MitraClip (MC; Abbott, Inc.) has become the
most frequently used percutaneous modality to treat signiﬁcant mitral regurgitation
(MR) in patients (pts) not amenable for surgery. Vena contracta area (VCA), measured
intraprocedurally via 3-dimensional transesophageal echocardiography, is a novel
parameter reﬂecting the severity of MR that is directly affected by the intervention and
can be used in the presence of multiple regurgitant jets. We sought to assess the impact
of post-MC VCA – along with other variables known to affect prognosis – on mor-
tality after MC therapy.
Methods: Included were 76 pts (median age 75 [IQR 68–80] years; LVEF 28 [23–33]
%; logistic EuroSCORE 22 [10–39] %; 55 men [72%]) who underwent MC therapy
for signiﬁcant functional MR (grade 3+ in 84%) and in whom VCA could be
determined post-MC. Pts were followed for 10.4 (median, range 0.3–23.1) months;
24 pts (32%) had died at 3.7 (0.3–18.9) months. Predictors of mortality were assessed
using Cox proportional-hazards regression analysis.
Results: MC therapy resulted in a median VCA of 17 (IQR 10–32) mm2. Variables
tested in univariate Cox models were age, LV ejection fraction, logistic EuroSCORE,
impaired renal function (GFR < 50ml/min), discharge MR grade, post-MC VCA,
and pre-MC tricuspid annular plane systolic excursion (TAPSE). Results are shown
in the Table. On multivariate analysis with a maximum of 2 variables, increasing
post-MC VCA (hazard ratio [HR] 1.02; 95% CI 1.00–1.04; p¼0.021) and decreasing
TAPSE (1.15; 1.03–1.28; p¼0.013) remained independently predictive of mortality.
A Cox model with ROC-derived cutoffs yielded HRs for post-MC VCA
>18mm2 of 2.39 (1.36–9.45; p¼0.052) and for TAPSE 13mm of 3.56 (1.36–9.35;
p¼0.010).Conclusions: Mortality after MC is independently impacted by decreasing TAPSE
and increasing post-MC VCA. MC therapy should aim for a VCA 18mm2.j September 13–17, 2014 j TCT Abstracts/Valvular disease - Mitraclip
